Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure
- 23 March 2017
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (2) , 223-231
Abstract
Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′‐GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP‐dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure.Linked Articles: This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetocKeywords
This publication has 76 references indexed in Scilit:
- Anti-Inflammatory and Cardioprotective Effects of Tadalafil in Diabetic MicePLOS ONE, 2012
- Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic EffectThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing HeartCirculation, 2010
- cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse MyocardiumThe Journal of Pharmacology and Experimental Therapeutics, 2009
- The phosphodiesterase‐5 inhibitor vardenafil improves cardiovascular dysfunction in experimental diabetes mellitusBritish Journal of Pharmacology, 2009
- Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3βJournal of Biological Chemistry, 2008
- SildenafilDrugs, 2008
- Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial KATP channels when administered at reperfusion following ischemia in rabbitsJournal of Molecular and Cellular Cardiology, 2007
- High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitorsBiochemical and Biophysical Research Communications, 2005
- Identification of Three Alternative First Exons and an Intronic Promoter of Human PDE5A GeneBiochemical and Biophysical Research Communications, 2000